PO.ADV02 · 患者倡导
弥合胰腺癌沟通鸿沟：一位IV期PDAC幸存者对改善创新研究与生物技术沟通的视角
Bridging the communication gap in pancreatic cancer: A stage IV PDAC survivor's perspective on improving research and biotech communication of innovation
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
尽管胰腺导管腺癌（PDAC）研究已取得重大进展，但生存率依然低下，部分原因在于科学创新向肿瘤科医生、患者及更广泛公众传播的方式中存在持续的鸿沟。作为一名长期IV期PDAC幸存者、患者顾问以及AACR科学家↔幸存者项目（Scientist↔Survivor Program）的参与者，我观察到许多有前景的进展——包括分子靶向治疗、生物标志物驱动的临床试验以及新兴诊断技术——在学术研究环境之外的转化仍不一致。在社区肿瘤诊疗环境中，医疗照护恰当地以标准治疗路径为中心；然而，对于新兴治疗选择的及时、实用信息获取有限，可能使患者（尤其是晚期疾病患者）无从知晓可能存在的额外治疗或临床试验机会。本海报呈现了一位幸存者视角下，阻碍研究者、生物技术公司、临床医生、患者与大众媒体之间有效沟通的结构性与文化性障碍。基于亲身经历、患者顾问角色以及与科学、临床和患者社群的互动，本文识别出若干关键挑战，包括研究成果传播的孤岛化、高度专业化的信息表达、临床实践中的时间限制，以及缺乏可信赖、以患者为中心的转化机制。基于这些观察，本海报提出了一个概念框架，以改善PDAC创新的沟通，该框架在研究传播、临床教育和公众参与中及早且持续地纳入幸存者的声音。所建议的策略包括：针对临床医生的简明新兴数据摘要、共同创建的患者教育资源，以及负责任地利用大众媒体和数字平台以准确阐释创新的背景。通过将沟通定位为癌症照护的关键组成部分而非下游活动，这一由幸存者提供参考的框架凸显了提高对新兴疗法和临床试验的认知、支持共同决策以及减少胰腺癌患者错失机会的可能性。
查看英文原文 English abstract
Despite significant advances in pancreatic ductaladenocarcinoma (PDAC) research, survival rates remain low, in part due topersistent gaps in how scientific innovation is communicated to oncologists,patients, and the broader public. As a long-term Stage IV PDAC survivor,patient advisor, and participant in the AACR Scientist↔Survivor Program, I haveobserved that many promising developments, including molecularly targetedtherapies, biomarker-driven trials, and emerging diagnostic technologies,remain inconsistently translated beyond academic research settings. Incommunity oncology settings, care appropriately centers on standardof-carepathways; however, limited access to timely, practical information aboutemerging options can leave patients, particularly those with advanced disease,unaware that additional therapeutic or trial options may exist. This posterpresents a survivor-informed perspective on structural and cultural barriersthat impede effective communication among researchers, biotechnology companies,clinicians, patients, and mass media. Drawing from lived experience, patientadvisory roles, and engagement with scientific, clinical, and patientcommunities, key challenges are identified, including siloed dissemination ofresearch findings, highly technical messaging, time constraints in clinicalpractice, and the absence of trusted, patient-centered translation mechanisms.Based on these observations, the poster proposes a conceptual framework toimprove the communication of PDAC innovation that integrates survivor voicesearly and consistently across research dissemination, clinical education, andpublic engagement. Recommended strategies include concise, clinician-focusedsummaries of emerging data, co-created patient education resources, andresponsible use of mass media and digital platforms to accurately contextualizeinnovation. By positioning communication as a critical component of cancercare, rather than a downstream activity, this survivor-informed frameworkhighlights opportunities to improve awareness of emerging therapies andclinical trials, support shared decision-making, and reduce missedopportunities for patients with pancreatic cancer.